Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: A placebo-controlled trial in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 3, 2004, Pages 1153-1159

  Winkler, Karl ^a,d   Abletshauser, Claudia ^b   Friedrich, Isolde ^a   Hoffmann, Michael M ^a   Wieland, Heinrich ^a   März, Winfried ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Novartis Pharma GmbH   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENDER; HUMAN; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SLOW DRUG RELEASE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PLACEBOS;

EID: 1642266640     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031494     Document Type: Article

References (35)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH 1997 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
4. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB 1999 C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242
5. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
6. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA 1995 Platelet-activating factor: a mediator for clinicians. J Intern Med 238:5-20
7. Evangelou AM 1994 Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 50:1-28
8. Tjoelker LW, Stafforini DM 2000 Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 1488:102-123
9. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E 1995 PAF-degrading acetylhydrolase is preferentially associated with dense LDL and very LDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 15:1764-1773
10. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM 1999 Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274:7018-7024
11. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM 1999 Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338:479-487
12. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H 1999 Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 100:1280-1284
13. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ 1999 Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 19:1284-1290
14. Itabe H 1998 Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 37:181-207
15. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD 1997 Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 27:595-602
16. Murakami M, Kudo I 2002 Phospholipase A2. J Biochem (Tokyo) 131:285-292
17. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD 2000 Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155
18. Leach CA, Hickey DM, Ife RJ, Macphee CH, Smith SA, Tew DG 2001 Lipoprotein-associated PLA2 inhibition - a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco 56:45-50
19. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM 1993 Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 92:141-146
20. Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, März W 2002 Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 87:5485-5490
21. Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, Tanaseanu S, Moldoveanu E 2002 Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 6:643-647
22. Blencowe C, Hermetter A, Kostner GM, Deigner HP 1995 Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 270:31151-31157
23. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosanto M, Mizuno K 2000 Spectrophotometric assay for serum plateet-activating factor acetylhydrolase activity. Clin Chim Acta 296:151-161
24. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J 1990 Structure of human low-density lipoprotein subfractions, determined by x-ray small-angle scattering. Biochim Biophys Acta 1037:48-57
25. Winkler K, Wetzka B, Hoffmann MM, Friedrich I, Kinner M, Baumstark MW, Zahradnik H-P, Wieland H, März W 2003 Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J Clin Endocrinol Metab 88:1162-1166
26. Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W 2003 Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension. A double-blind, placebo-controlled study. Diabetes Care 26:2588-2594
27. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
28. Tsoukatos DC, Liapikos TA, Tselepis AD, Chapman MJ, Ninio E 2001 Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Biochem J 357:457-464
29. Balboa MA, Perez R, Balsinde J 2003 Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid. J Immunol 171:989-994
30. Habenicht AJR, Salbach P, Goering M, Zeh W, Janssen-Timmen U, Blattner C, Kling WC, Glomset JA 1990 The LDL receptor pathway delivers arachidonic acid for eicosanoid formation in cells stimulated by platelet-derived growth factor. Nature 345:634-636
31. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J 1996 Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261-271
32. Weisser B, Locher R, de Graaf J, Moser R, Sachinidis A, Vetter W 1993 Low density lipoprotein subfractions increase thromboxane formation in endothelialn cells. Biochem Biophys Res Commun 192:1245-1250
33. Kudolo GB, Bressler P, DeFronzo RA 1997 Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal 17:97-113
34. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD 2002 Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22:306-311
35. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, Thillet J 2002 Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164:305-311